Dovitinib lactate is primarily used in the treatment of various types of cancers, particularly those involving abnormal tyrosine kinase activity. It is effective in targeting and inhibiting multiple tyrosine kinases, which play a crucial role in the growth and spread of cancer cells. This makes it a valuable option for treating renal cell carcinoma, gastrointestinal stromal tumors, and certain types of breast cancer. Additionally, it has shown promise in clinical trials for its potential to combat other solid tumors by disrupting signaling pathways that promote tumor progression. Its ability to target multiple kinases also makes it a candidate for combination therapies, enhancing the overall efficacy of cancer treatment regimens.